|

Locally Advanced Resectable Head and Neck Squamous Cell Carcinoma: A Prospective, Single-Arm Clinical Study

RECRUITINGPhase 2Sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Actively Recruiting
PhasePhase 2
SponsorCancer Institute and Hospital, Chinese Academy of Medical Sciences
Started2026-09-02
Est. completion2028-10
Eligibility
Age18 Years – 75 Years
Healthy vol.Accepted

Summary

This is a prospective, single-arm, phase II study. It aims to evaluate whether neoadjuvant targeted therapy combined with immunotherapy and chemotherapy is effective and safe in patients with locally advanced, resectable head and neck squamous cell carcinoma (HNSCC).

Eligibility

Age: 18 Years – 75 YearsHealthy volunteers accepted
Inclusion Criteria:

* Age 18-75 years.
* Histologically or cytologically confirmed resectable stage III-IVB head and neck squamous cell carcinoma (HNSCC) of the oral cavity, oropharynx, hypopharynx, or larynx according to the AJCC 9th edition.
* For oropharyngeal cancer, tumor tissue must be available for HPV/P16 testing (testing is not required if previously performed).
* Tumor tissue (from the primary tumor or resected tumor) must be available for EGFR and PD-L1 immunohistochemical testing (testing is not required if previously performed); genetic testing may be performed when necessary.
* ECOG performance status 0-1.
* At least one measurable lesion according to RECIST 1.1.
* Expected survival ≥6 months.
* Adequate hematologic function: white blood cell count ≥3 × 10\^9/L; absolute neutrophil count ≥1.5 × 10\^9/L; platelet count ≥100 × 10\^9/L; hemoglobin ≥90 g/L.
* Adequate renal function: serum creatinine ≤1.5 × ULN or creatinine clearance (CrCl) \>50 mL/min (using the Cockcroft-Gault formula):
* Female CrCl = (140 - age) × body weight (kg) × 0.85 / (72 × Scr mg/dL); Male CrCl = (140 - age) × body weight (kg) × 1.00 / (72 × Scr mg/dL).
* Adequate hepatic function: total serum bilirubin ≤1.5 × ULN; aspartate aminotransferase (AST) ≤2.5 × ULN; alanine aminotransferase (ALT) ≤2.5 × ULN.
* Women of childbearing potential must have a negative pregnancy test within 2 weeks before the start of study treatment and must not be breastfeeding. -Female participants must agree to use effective contraception during the study and for 6 months after the last dose of study drug. Male participants must agree to use effective contraception during the study and for 6 months after the last dose of study drug.
* Participants must voluntarily agree to participate, provide written informed consent, and be able to comply with the study visits and procedures specified in the protocol.

Exclusion Criteria:

* Prior radiotherapy or chemotherapy; prior immunotherapy targeting PD-1/PD-L1; prior EGFR monoclonal antibody, EGFR-TKI, or anti-angiogenic therapy.
* Treatment with systemic or local corticosteroids within 4 weeks before enrollment.
* HIV-positive; HBsAg-positive with detectable HBV DNA (quantitative ≥1000 copies/mL); or positive blood screening for chronic hepatitis C (HCV antibody-positive) with detectable HCV RNA.
* Participation in another interventional clinical trial within 30 days before screening.
* History of other malignancies (except cured basal cell carcinoma of the skin). History of primary immunodeficiency.
* Presence of poorly controlled concomitant diseases (e.g., heart failure, severe pulmonary disease, severe liver disease, psychiatric disorders, etc.).
* Major surgery within 90 days before the first dose of study drug or planned surgery.
* Known allergy to any study drug or its components.
* Pregnancy (confirmed by blood or urine HCG) or breastfeeding; or participants of childbearing potential (both male and female) who are unwilling or unable to use effective contraception until at least 6 months after the last study treatment.
* Any condition that, in the investigator's opinion, makes the participant unsuitable for the study.
* Unwillingness to participate in the study or inability to sign informed consent.

Receipt of a live vaccine within 30 days before study drug administration.

Conditions2

CancerHead and Neck Squamous Cell Carcinoma

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.